RxSight(US:RXST) Prnewswire·2025-08-09 12:12Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of false and misleading statements regarding the company's performance and financial guidance, particularly following a significant drop in stock price after disappointing financial results [2][4][5]. Group 1: Company Performance and Allegations - The complaint against RxSight alleges that the company and its executives violated federal securities laws by failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [4]. - RxSight overstated the demand for its products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full year 2025 guidance by approximately $42.5 million at the midpoint [5]. Group 2: Stock Market Reaction - On July 9, 2025, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share, following the announcement of disappointing financial results and guidance [5]. Group 3: Legal Proceedings - Investors who purchased or acquired securities in RxSight between November 7, 2024, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of September 22, 2025, to seek the role of lead plaintiff in a federal securities class action [2][6].